$ALNY
ALNYLAM PHARMACEUTICALS, INC.

2023 Q2 Form 10-Q Financial Statement

#000117867023000011 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $318.8M $319.3M
YoY Change 41.78% 49.72%
Cost Of Revenue $85.37M $41.43M
YoY Change 150.81% 76.63%
Gross Profit $233.4M $277.9M
YoY Change 22.33% 46.39%
Gross Profit Margin 73.22% 87.02%
Selling, General & Admin $214.7M $183.7M
YoY Change 26.3% 18.9%
% of Gross Profit 91.99% 66.1%
Research & Development $248.5M $230.6M
YoY Change 20.81% 35.71%
% of Gross Profit 106.49% 82.98%
Depreciation & Amortization $13.18M $14.07M
YoY Change 30.52% 48.68%
% of Gross Profit 5.65% 5.06%
Operating Expenses $463.2M $414.2M
YoY Change 23.3% 27.7%
Operating Profit -$229.8M -$149.8M
YoY Change 19.9% 2.1%
Interest Expense -$37.78M $28.96M
YoY Change -188.65% -31.65%
% of Operating Profit
Other Income/Expense, Net -$6.603M -$22.56M
YoY Change -92.04% -75.65%
Pretax Income -$274.2M -$172.4M
YoY Change -0.17% -27.99%
Income Tax $1.815M $1.739M
% Of Pretax Income
Net Earnings -$276.0M -$174.1M
YoY Change -0.5% -27.56%
Net Earnings / Revenue -86.59% -54.53%
Basic Earnings Per Share -$2.21 -$1.40
Diluted Earnings Per Share -$2.21 -$1.40
COMMON SHARES
Basic Shares Outstanding 124.5M shares 124.1M shares
Diluted Shares Outstanding 124.7M shares 124.1M shares

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.058B $2.045B
YoY Change -1.07% -7.37%
Cash & Equivalents $657.8M $672.2M
Short-Term Investments $1.400B $1.373B
Other Short-Term Assets $145.5M $119.0M
YoY Change 12.08% 3.45%
Inventory $100.5M $131.9M
Prepaid Expenses
Receivables $192.5M $219.4M
Other Receivables $28.13M $22.57M
Total Short-Term Assets $2.524B $2.541B
YoY Change 2.12% -1.88%
LONG-TERM ASSETS
Property, Plant & Equipment $736.3M $523.0M
YoY Change 44.88% 3.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $142.1M $63.45M
YoY Change 83.87% -9.12%
Total Long-Term Assets $878.3M $850.9M
YoY Change 2.28% 0.84%
TOTAL ASSETS
Total Short-Term Assets $2.524B $2.541B
Total Long-Term Assets $878.3M $850.9M
Total Assets $3.402B $3.392B
YoY Change 2.16% -1.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $59.75M $62.24M
YoY Change 13.98% 13.33%
Accrued Expenses $640.6M $508.6M
YoY Change 52.07% 42.89%
Deferred Revenue $54.64M $35.79M
YoY Change -52.19% -72.85%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $788.6M $673.4M
YoY Change 19.91% 11.13%
LONG-TERM LIABILITIES
Long-Term Debt $1.019B $1.018B
YoY Change 50.33% 50.42%
Other Long-Term Liabilities $2.003B $224.0M
YoY Change 1173.38% 85.43%
Total Long-Term Liabilities $3.022B $224.0M
YoY Change 1821.09% 85.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $788.6M $673.4M
Total Long-Term Liabilities $3.022B $224.0M
Total Liabilities $3.811B $3.651B
YoY Change 20.8% 20.41%
SHAREHOLDERS EQUITY
Retained Earnings -$7.019B -$6.743B
YoY Change 17.86% 18.75%
Common Stock $6.648B $6.523B
YoY Change 7.68% 6.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$408.1M -$259.2M
YoY Change
Total Liabilities & Shareholders Equity $3.402B $3.392B
YoY Change 2.16% -1.21%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$276.0M -$174.1M
YoY Change -0.5% -27.56%
Depreciation, Depletion And Amortization $13.18M $14.07M
YoY Change 30.52% 48.68%
Cash From Operating Activities -$58.99M -$166.5M
YoY Change -51.97% -2.76%
INVESTING ACTIVITIES
Capital Expenditures $15.92M $13.89M
YoY Change -199.15% -22.22%
Acquisitions
YoY Change
Other Investing Activities $7.206M $0.00
YoY Change -95.46% -100.0%
Cash From Investing Activities -$8.713M -$76.22M
YoY Change -106.1% -48.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 53.39M $46.37M
YoY Change 76.0% 32.66%
NET CHANGE
Cash From Operating Activities -58.99M -$166.5M
Cash From Investing Activities -8.713M -$76.22M
Cash From Financing Activities 53.39M $46.37M
Net Change In Cash -14.31M -$194.1M
YoY Change -128.43% -32.09%
FREE CASH FLOW
Cash From Operating Activities -$58.99M -$166.5M
Capital Expenditures $15.92M $13.89M
Free Cash Flow -$74.91M -$180.4M
YoY Change -29.84% -4.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001178670
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36407
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ALNYLAM PHARMACEUTICALS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0602661
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
675 West Kendall Street,
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Henri A. Termeer Square
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
CY2023Q1 dei City Area Code
CityAreaCode
617
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
551-8200
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
ALNY
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
124525737 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
672245000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
866394000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1372574000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1297890000 usd
CY2023Q1 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
25856000 usd
CY2022Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
28122000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
219434000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
237963000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
131879000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
128962000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
119030000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
132916000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
2541018000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2692247000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
523032000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
523494000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
215049000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
215136000 usd
CY2023Q1 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
49388000 usd
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
49390000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
63453000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
66092000 usd
CY2023Q1 us-gaap Assets
Assets
3391940000 usd
CY2022Q4 us-gaap Assets
Assets
3546359000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
62237000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
98094000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
508599000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
545460000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
43055000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
41967000 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
35794000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
42105000 usd
CY2023Q1 alny Royalty Liability Current
RoyaltyLiabilityCurrent
23706000 usd
CY2022Q4 alny Royalty Liability Current
RoyaltyLiabilityCurrent
40289000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
673391000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
767915000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
259399000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
261339000 usd
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
191257000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
193791000 usd
CY2023Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1017887000 usd
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1016942000 usd
CY2023Q1 alny Royalty Liability Noncurrent
RoyaltyLiabilityNoncurrent
1285200000 usd
CY2022Q4 alny Royalty Liability Noncurrent
RoyaltyLiabilityNoncurrent
1252015000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
224046000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
212580000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
3651180000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3704582000 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
124241000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
124241000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
123925000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
123925000 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1243000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1240000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
6522091000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
6454540000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-39124000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-44654000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6743450000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6569349000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-259240000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-158223000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3391940000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3546359000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
319290000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
213259000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
41432000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23457000 usd
CY2023Q1 alny Cost Of Collaboration Manufacturing And Royalties
CostOfCollaborationManufacturingAndRoyalties
13437000 usd
CY2022Q1 alny Cost Of Collaboration Manufacturing And Royalties
CostOfCollaborationManufacturingAndRoyalties
12170000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
230569000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
169893000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
183659000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
154471000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
469097000 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
359991000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-149807000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-146732000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
28955000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
42362000 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
18655000 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1012000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12255000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-51274000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22555000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-92624000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-172362000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-239356000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1739000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
985000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-174101000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-240341000 usd
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.40
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.00
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.00
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
124111000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
124111000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
120393000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
120393000 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-174101000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-240341000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4125000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7217000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1410000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2376000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
5000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-35000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5530000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4806000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-168571000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-245147000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-158223000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26418000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
41136000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5530000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-174101000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-259240000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
588203000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28059000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30051000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4806000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-240341000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
401166000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-174101000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-240341000 usd
CY2023Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
14065000 usd
CY2022Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
9460000 usd
CY2023Q1 alny Amortization And Interest Accretion Related To Operating Leases
AmortizationAndInterestAccretionRelatedToOperatingLeases
12014000 usd
CY2022Q1 alny Amortization And Interest Accretion Related To Operating Leases
AmortizationAndInterestAccretionRelatedToOperatingLeases
10318000 usd
CY2023Q1 alny Non Cash Interest Expense On Sale Of Future Royalties
NonCashInterestExpenseOnSaleOfFutureRoyalties
25275000 usd
CY2022Q1 alny Non Cash Interest Expense On Sale Of Future Royalties
NonCashInterestExpenseOnSaleOfFutureRoyalties
27702000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
39947000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
29293000 usd
CY2023Q1 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-2267000 usd
CY2022Q1 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-31161000 usd
CY2023Q1 alny Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
-6471000 usd
CY2022Q1 alny Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
-13782000 usd
CY2023Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-6276000 usd
CY2022Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
7395000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-19153000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-39696000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
403000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1926000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1235000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
29852000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-81975000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-48736000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-12827000 usd
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-10672000 usd
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8850000 usd
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-12325000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-166475000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-171193000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13891000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17859000 usd
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
435746000 usd
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
634705000 usd
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
373420000 usd
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
505220000 usd
CY2023Q1 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
49225000 usd
CY2022Q1 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
9400000 usd
CY2023Q1 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
49225000 usd
CY2022Q1 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
9400000 usd
CY2023Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 usd
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
75000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-76217000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-147419000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
42371000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
27123000 usd
CY2023Q1 us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
4000000 usd
CY2022Q1 us-gaap Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
7833000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46371000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34956000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2176000 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2238000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-194145000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-285894000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
868556000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
822153000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
674411000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
536259000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
13912000 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
14120000 usd
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4034000 usd
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8318000 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
NATURE OF BUSINESS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on ribonucleic acid interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which focuses on our planned transition to a top-tier biotech company by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, while delivering exceptional financial performance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2023, we have five marketed products, including one partnered product, and multiple late-stage investigational programs advancing towards potential commercialization. We currently generate worldwide product revenues from four commercialized products, ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO, primarily in the United States, or U.S., Europe and Japan.</span></div>
CY2023Q1 alny Number Of Marketed Products
NumberOfMarketedProducts
5 product
CY2023Q1 alny Number Of Partnered Products
NumberOfPartneredProducts
1 product
CY2023Q1 alny Number Of Commercialized Products
NumberOfCommercializedProducts
4 product
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div>
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
15400000 usd
CY2022Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
9500000 usd
CY2023Q1 alny Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-5700000 usd
CY2022Q1 alny Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
-3900000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1382107000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
621000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5966000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1376762000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1420603000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
119000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9589000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1411133000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1372574000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1297890000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
4188000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
113243000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1376762000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1411133000 usd
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
22875000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
22315000 usd
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
110976000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
113783000 usd
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
29534000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
25606000 usd
CY2023Q1 alny Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
163385000 usd
CY2022Q4 alny Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
161704000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
672245000 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
534081000 usd
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
2166000 usd
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
2178000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
674411000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
536259000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
1401000 usd
CY2023Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-4129000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5530000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
2377000 usd
CY2022Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
7183000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4806000 usd
CY2023Q1 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.12
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14703000 shares
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39947000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29293000 usd
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14591000 shares

Files In Submission

Name View Source Status
0001178670-23-000011-index-headers.html Edgar Link pending
0001178670-23-000011-index.html Edgar Link pending
0001178670-23-000011.txt Edgar Link pending
0001178670-23-000011-xbrl.zip Edgar Link pending
alny-20230331.htm Edgar Link pending
alny-20230331.xsd Edgar Link pending
alny-20230331_g1.jpg Edgar Link pending
alny2023q110-qex311.htm Edgar Link pending
alny2023q110-qex312.htm Edgar Link pending
alny2023q110-qex321.htm Edgar Link pending
alny2023q110-qex322.htm Edgar Link pending
alny2023q1exhibit101.htm Edgar Link pending
alny2023q1exhibit102.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
alny-20230331_cal.xml Edgar Link unprocessable
alny-20230331_pre.xml Edgar Link unprocessable
alny-20230331_def.xml Edgar Link unprocessable
alny-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
alny-20230331_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending